Suppliers and packagers for generic pharmaceutical drug: succimer

succimer

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Recordati Rare	CHEMET	succimer	CAPSULE;ORAL	019998	NDA	Recordati Rare Diseases, Inc.	55292-201-11	100 CAPSULE in 1 BOTTLE (55292-201-11)	2013-08-21

SUCCIMER (DMSA) Pharmaceutical Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supplier landscape for succimer (dimercaptosuccinic acid or DMSA), a chelating agent used to treat lead poisoning. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and contract manufacturing organizations (CMOs) involved in its production.

Key Suppliers and Their Capabilities

What are the primary API manufacturers of Succimer?

The manufacturing of succimer API is concentrated among a limited number of specialized chemical producers. Key suppliers include:

• Wallace Pharmaceuticals Pvt. Ltd. (India): This company is a significant manufacturer of succimer API. Their facilities are often described as meeting current Good Manufacturing Practices (cGMP). Wallace Pharmaceuticals has been noted for its role in supplying this critical API to various markets.
• Shaanxi JinHui Pharmaceutical Co., Ltd. (China): Another prominent supplier, Shaanxi JinHui Pharmaceutical, produces succimer API. Their production capacity and adherence to quality standards are crucial for global supply chain stability.
• Other Manufacturers: While specific names can fluctuate due to market dynamics and regulatory approvals, other API manufacturers in India and China are known to produce succimer, often catering to generic pharmaceutical formulations.

These manufacturers are essential for ensuring a consistent and quality-assured supply of the core succimer molecule. Their manufacturing processes are subject to regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What role do excipient suppliers play in Succimer formulation?

Excipients are inactive ingredients in pharmaceutical formulations that are critical for drug delivery, stability, and patient compliance. For succimer, commonly used excipients include:

• Binders: Such as microcrystalline cellulose or povidone, which hold the tablet together.
• Disintegrants: Like croscarmellose sodium or sodium starch glycolate, which help the tablet break apart in the digestive tract.
• Fillers/Diluents: Such as lactose or calcium phosphate, used to add bulk to the formulation.
• Lubricants: Including magnesium stearate or stearic acid, which prevent the tablet from sticking to manufacturing equipment.
• Coating Agents: For film-coated tablets, which can improve taste, ease of swallowing, and stability. Common agents include hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG).

Major global excipient suppliers that would likely serve succimer manufacturers include:

• Dow Inc.: A leading supplier of cellulose-based excipients (e.g., HPMC for coatings).
• BASF SE: Offers a broad range of pharmaceutical excipients, including binders and disintegrants.
• Ashland Global Holdings Inc.: Provides specialty excipients for drug formulation.
• Roquette Frères: A key producer of starch-based excipients and other functional ingredients.
• JRS Pharma: Supplies cellulose and starch-based excipients.

The selection and quality of these excipients are paramount to the efficacy, safety, and manufacturability of the final succimer drug product.

Which Contract Manufacturing Organizations (CMOs) are involved in Succimer production?

CMOs play a vital role in the pharmaceutical industry by providing manufacturing services for drug products, including formulation, tableting, packaging, and quality control. For succimer, CMOs are instrumental in transforming the API and excipients into finished dosage forms.

While specific CMOs handling succimer may not always be publicly disclosed due to client confidentiality, companies with broad capabilities in oral solid dosage manufacturing are likely involved. These include:

• Catalent Pharma Solutions: A large global CDMO with extensive experience in tableting, coating, and packaging.
• Thermo Fisher Scientific (Patheon): Another major CDMO offering comprehensive drug substance and drug product manufacturing services.
• Lonza Group AG: Provides integrated services from API to finished dosage forms, including oral solids.
• Recipharm AB: A leading European CDMO with capabilities in solid dosage manufacturing.
• Contract Development and Manufacturing Organization (CDMO) Market Players in India: Numerous Indian CMOs, such as Divi's Laboratories Limited (though primarily an API manufacturer, they can have finished dosage capabilities) and Divyas Pharmaceuticals & Biologicals Ltd., are significant players in global pharmaceutical manufacturing and could be involved.

The engagement of CMOs allows pharmaceutical companies to leverage specialized manufacturing expertise, capacity, and regulatory compliance without direct investment in their own facilities for specific products like succimer.

Regulatory Landscape and Quality Control

What are the key regulatory requirements for Succimer manufacturing?

The manufacturing of succimer API and its finished drug product is subject to stringent regulatory requirements to ensure patient safety and product efficacy. These include:

• Current Good Manufacturing Practices (cGMP): Mandated by regulatory bodies like the FDA (21 CFR Parts 210 and 211) and EMA, cGMP ensures that drugs are consistently produced and controlled according to quality standards. This covers all aspects of production, from raw materials and premises to equipment and the training of staff.
• API Master Files (APIMFs) / Drug Master Files (DMFs): API manufacturers typically submit detailed information about their manufacturing process, facilities, and quality controls to regulatory agencies in DMFs. These are referenced by finished drug product manufacturers in their own regulatory submissions (e.g., Abbreviated New Drug Applications - ANDAs).
• Impurity Profiling: Rigorous testing for impurities, including related substances and residual solvents, is required. Limits are set by pharmacopoeias (e.g., USP, EP) and regulatory guidance (e.g., ICH guidelines).
• Stability Testing: Manufacturers must conduct stability studies to determine the shelf-life of the API and finished product under various storage conditions.
• Pharmacopoeial Standards: Succimer must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define identity, strength, quality, and purity criteria.
• Batch-to-Batch Consistency: Manufacturers must demonstrate consistent production quality across all batches.

Adherence to these regulations is critical for market access and continued supply.

How is the quality of Succimer API assured?

Quality assurance for succimer API involves a multi-faceted approach:

• Raw Material Testing: Incoming raw materials used in succimer synthesis are tested against predefined specifications.
• In-Process Controls (IPCs): Critical steps during the synthesis process are monitored to ensure reactions proceed as expected and intermediates meet quality standards.
• Finished API Testing: The final succimer API undergoes comprehensive testing, including:
  • Assay: Determining the percentage of pure succimer.
  • Identification Tests: Confirming the chemical identity (e.g., via infrared spectroscopy).
  • Related Substances: Quantifying and identifying any impurities.
  • Residual Solvents: Measuring any remaining solvents from the manufacturing process (ICH Q3C).
  • Heavy Metals: Testing for the presence of toxic metals.
  • Loss on Drying/Water Content: Determining moisture levels.
  • Particle Size Distribution: Relevant for formulation and dissolution.
• Audits and Certifications: API manufacturers undergo regular audits by their pharmaceutical clients and regulatory agencies. Certifications (e.g., ISO) can also indicate a commitment to quality management systems.
• Supplier Qualification: Finished product manufacturers rigorously qualify their API suppliers, often requiring site visits, detailed questionnaires, and review of quality agreements.

What are the global pharmacopoeial standards for Succimer?

Major pharmacopoeias provide the official standards for succimer. Compliance with these standards is typically a prerequisite for marketing a drug product in a given region.

• United States Pharmacopeia (USP): The USP monograph for Succimer includes tests for Identification, Assay, Related Compounds, Heavy Metals, and Water Content. The typical dosage form recognized is capsules.
• European Pharmacopoeia (EP): The EP monograph for Acidum Succinicum (succinic acid, a related substance and potential precursor but not succimer itself) and the monograph for Succimer detail its specifications, including tests for appearance, solubility, identification, related substances, and assay. The EP typically refers to succimer for oral administration.

These pharmacopoeias are regularly updated, requiring manufacturers to stay abreast of the latest requirements.

Supply Chain Risks and Mitigation Strategies

What are the potential supply chain disruptions for Succimer?

The succimer supply chain, like many pharmaceutical supply chains, is vulnerable to several risks:

• Raw Material Sourcing: Dependence on specific chemical precursors or intermediates from a limited number of suppliers can create bottlenecks. Geopolitical instability or natural disasters affecting these primary suppliers can halt production.
• Manufacturing Capacity: A limited number of cGMP-compliant API manufacturers means that any disruption at one facility (e.g., equipment failure, regulatory action) can significantly impact global supply.
• Regulatory Scrutiny: Increased regulatory inspections or changes in regulatory requirements can lead to production stoppages or delays. Issues identified during audits can result in the delisting of a supplier.
• Logistics and Transportation: Global shipping disruptions, customs delays, or increases in freight costs can affect the timely delivery of API and finished products.
• Quality Incidents: A significant quality failure at an API or CMO site could lead to product recalls and a sudden shortage.
• Geographic Concentration of Manufacturing: A heavy reliance on manufacturers in specific regions (e.g., India, China) can expose the supply chain to country-specific risks (e.g., trade disputes, pandemic-related lockdowns).

How can pharmaceutical companies mitigate these supply chain risks?

Effective risk mitigation strategies are crucial for ensuring the continuous availability of succimer:

• Dual Sourcing: Qualifying and maintaining relationships with at least two distinct API manufacturers, preferably in different geographic regions, can provide redundancy.
• Strategic Stockpiling: Maintaining buffer stocks of critical API and finished product at strategic locations can provide a cushion against short-term supply disruptions.
• Robust Supplier Qualification and Auditing Programs: Thoroughly vetting potential suppliers and conducting regular audits ensures that manufacturing partners meet quality and compliance standards. This includes assessing their business continuity plans.
• Supply Chain Transparency: Gaining visibility into lower-tier suppliers (e.g., suppliers of key raw materials to the API manufacturer) can help identify and address upstream risks.
• Long-Term Contracts: Securing long-term supply agreements with key manufacturers can ensure preferential allocation and stable pricing.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including identifying alternative CMOs or logistics providers, is essential.
• Regulatory Intelligence: Proactively monitoring regulatory changes and guidance in key markets allows companies to adapt their manufacturing and quality processes.
• Collaboration and Information Sharing: Engaging with industry associations and peers can provide insights into emerging supply chain trends and best practices.

Market Dynamics and Future Outlook

What is the current market size and demand for Succimer?

The market for succimer is primarily driven by its use in treating lead poisoning, particularly in children. Demand is influenced by:

• Prevalence of Lead Exposure: Public health initiatives aimed at reducing lead exposure and increased awareness of its dangers can influence demand. Environmental factors, such as aging infrastructure with lead pipes, also play a role.
• Pediatric Health Trends: The incidence of childhood lead poisoning directly correlates with the demand for effective chelating agents like succimer.
• Healthcare Reimbursement Policies: Insurance coverage and government programs for lead poisoning treatment impact patient access and overall demand.

Estimating the precise global market size for succimer can be challenging as it is often categorized within the broader chelation therapy or heavy metal detoxification market. However, it is a niche but critical pharmaceutical product. The market is generally stable, driven by ongoing public health concerns regarding lead. Growth is likely to be incremental, tied to public health initiatives and diagnostic improvements rather than rapid expansion.

What are the key trends impacting Succimer supply?

Several trends are shaping the succimer supply chain:

• Increased Regulatory Scrutiny: Regulatory bodies globally are intensifying inspections and quality assessments, placing greater demands on manufacturers to maintain high compliance standards. This can lead to the weeding out of less compliant suppliers.
• Consolidation in CMO and API Manufacturing: The pharmaceutical manufacturing sector is experiencing consolidation. This could lead to fewer, larger players in the succimer API and CMO space, potentially affecting supplier diversity.
• Focus on Supply Chain Resilience: Recent global events have highlighted the fragility of pharmaceutical supply chains, leading to increased emphasis on resilience, diversification, and robust risk management strategies by pharmaceutical companies.
• Technological Advancements in Manufacturing: While succimer synthesis is a mature process, ongoing advancements in process analytical technology (PAT) and continuous manufacturing could offer efficiencies and improved quality control for API production, though adoption for established generics may be slower.
• Sustainability in Chemical Manufacturing: Increasing pressure for environmentally sustainable chemical synthesis processes may influence the choice of raw materials and manufacturing methods by API producers.

What is the future outlook for Succimer suppliers?

The future outlook for succimer suppliers is characterized by a focus on reliability, quality, and compliance.

• API Manufacturers: Suppliers who consistently demonstrate high quality, robust regulatory compliance, and secure supply chains will remain preferred partners. Companies with diversified manufacturing footprints and strong quality management systems are well-positioned.
• Excipient Suppliers: The demand for high-purity, pharmacopoeial-grade excipients will continue. Suppliers offering comprehensive technical support and consistent quality will be valued.
• CMOs: CMOs that can offer flexible manufacturing capacities, excel in solid oral dosage forms, and maintain impeccable regulatory records will be in demand. The ability to support complex formulations or specialized packaging may also become a differentiator.

The market for succimer is unlikely to see dramatic growth, but its essential nature for treating lead poisoning ensures sustained demand. Suppliers who can navigate the evolving regulatory landscape and demonstrate unwavering commitment to quality and supply chain integrity will succeed.

Key Takeaways

• Succimer API manufacturing is primarily concentrated among specialized chemical producers in India and China. Key players include Wallace Pharmaceuticals Pvt. Ltd. and Shaanxi JinHui Pharmaceutical Co., Ltd.
• A broad range of global excipient suppliers, including Dow Inc., BASF SE, and Ashland Global Holdings Inc., provide critical inactive ingredients for succimer formulations.
• Contract Manufacturing Organizations (CMOs) such as Catalent Pharma Solutions and Thermo Fisher Scientific (Patheon) are instrumental in producing finished succimer dosage forms.
• Adherence to stringent regulatory requirements, including cGMP, pharmacopoeial standards (USP, EP), and impurity control, is mandatory for all succimer supply chain participants.
• Supply chain risks for succimer include raw material dependency, manufacturing capacity limitations, regulatory actions, and logistical challenges. Mitigation strategies such as dual sourcing, stockpiling, and robust supplier qualification are essential.
• The market for succimer is driven by public health concerns related to lead poisoning, with demand remaining stable.
• Future trends favor suppliers demonstrating consistent quality, strong regulatory compliance, supply chain resilience, and proactive risk management.

Frequently Asked Questions

1. How is succimer synthesized, and what are the key starting materials?

Succimer is synthesized through a multi-step chemical process. A common route involves the reaction of maleic anhydride with thioglycolic acid to form dimercaptosuccinic acid. Key starting materials include maleic anhydride and thioglycolic acid, which themselves are products of basic organic chemical manufacturing. The purity and quality of these starting materials are critical for the successful synthesis of pharmaceutical-grade succimer.

2. What are the typical storage conditions for succimer API and finished products?

Succimer API and finished drug products are typically stored under controlled room temperature conditions, protected from light and moisture. Specific requirements are detailed in the manufacturer's specifications and regulatory filings, often aligned with ICH guidelines for stability testing (e.g., storage at 20-25°C with excursions permitted to 15-30°C for finished products). This helps maintain the drug's potency and prevent degradation over its shelf life.

3. Are there any alternative chelating agents for lead poisoning treatment, and how do they compare?

Yes, other chelating agents are used for lead poisoning, including edetate calcium disodium (CaNa2EDTA) and dimercaprol (BAL). CaNa2EDTA is typically administered intravenously or intramuscularly and is effective for more severe cases of lead poisoning, especially with neurological involvement. Dimercaprol is highly toxic and usually reserved for severe poisoning cases, often in conjunction with CaNa2EDTA. Succimer is preferred for less severe cases and is orally administered, making it more convenient for outpatient treatment, particularly in children.

4. How long does it typically take to qualify a new succimer API supplier?

Qualifying a new succimer API supplier is a rigorous process that can take anywhere from six months to over a year. It involves initial due diligence, questionnaires, detailed review of the manufacturer's quality systems and regulatory history, site audits by the pharmaceutical company's quality assurance team, and often the submission of stability data and product samples for evaluation. The process must satisfy the requirements of both the pharmaceutical company and the relevant regulatory authorities.

5. What is the patent landscape for succimer, and are there active composition-of-matter patents?

The original composition-of-matter patents for succimer have long expired. Succimer is a well-established, generic drug. The patent landscape for succimer primarily relates to potential new formulations, novel delivery systems, specific manufacturing processes, or methods of use that may have been developed more recently. However, these are typically incremental innovations rather than fundamental patents on the molecule itself. Pharmaceutical companies relying on succimer for their products focus on supply chain security and cost-effective manufacturing rather than patent protection for the core API.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/en/veterinary-regulatory/veterinary-medicines/good-manufacturing-practice-guidance [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines [4] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.usppf.com/ (Note: Access to specific monographs requires subscription.) [5] European Pharmacopoeia. (n.d.). European Pharmacopoeia Online. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-online (Note: Access to specific monographs requires subscription.) [6] Centers for Disease Control and Prevention. (n.d.). Lead Poisoning Prevention. Retrieved from https://www.cdc.gov/nceh/lead/